Genital Neoplasms, Female
Conditions
Keywords
ovarian cancer, cervical cancer, uterine cancer, fallopian tube cancer, endometrial cancer, vaginal cancer, peritoneal cancer, reproductive cancer
Brief summary
The aim of the trial is to determine the recommended phase II dose of weekly intravenous topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous temsirolimus in patients with and without prior pelvic radiation.
Interventions
DRUGTopotecan
Weekly doses via IV infusion. Dose will be assigned based on time of study entry.
DRUGCCI-779 (temsirolimus)
Weekly 25mg dose via IV infusion.
Sponsors
Wyeth is now a wholly owned subsidiary of Pfizer
University of Chicago
Study design
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed recurrent or metastatic ovarian carcinoma, fallopian tube carcinoma, primary peritoneal carcinoma, cervical carcinoma, endometrial carcinoma, vulvar carcinoma, vaginal carcinoma, or carcinosarcoma of the ovary, endometrium or cervix. * Prior Therapy: at least one and may have up to three prior cytotoxic chemotherapeutic regimens for the management of primary disease. * Must be at least 18 years of age. * GOG performance status must be 0 or 1. * Patients must have adequate organ and marrow function as defined below: * hemoglobin ≥10g/dL * absolute neutrophil count ≥1,500/uL * platelets ≥100,000/uL * total bilirubin below the institutional upper limit of normal * AST(SGOT)/ALT(SGPT) below the institutional upper limit of normal * creatinine below the institutional upper limit of normal * cholesterol ≤ 350 mg/dL (fasting) * triglycerides ≤ 400 mg/dL (fasting) * albumin ≥ 3.0 mg/dL * negative pregnancy test for women able to have children * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Prior therapy with topotecan * More than 3 prior cytotoxic chemotherapeutic regimens or treatment with temsirolimus or any other mTOR inhibitor * Concomitant hormonal therapy or radiation therapy * Clinically significant infections or other medical problems of significant severity * History of unstable angina or myocardial infarction within the past six months * Known brain metastases unless the metastases have been controlled by prior surgery or radiotherapy, and the patient has been neurologically stable and off of steroids for at least 4 weeks. * Any requirement for oxygen * Cannot be receiving potent enzyme-inducing antiepileptic drugs (EIAEDs; e.g., phenytoin, carbamazepine, phenobarbital) nor any other potent CYP3A4 inducer such as rifampin or St. John's wort, as these may decrease temsirolimus levels. Use of agents that potently inhibit CYP3A4 (and hence may raise temsirolimus levels), such as ketoconazole, is discouraged, but not specifically prohibited.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tolerability of regimen | 4 weeks |
Countries
United States
Outcome results
None listed